IP Library › Granted Patent US 12,691,085
Granted Patent B2
US 12,691,085 · App. 18/270,005 · Granted Jul 28, 2026

Cancer treatment composition and method

Inventor: Matthew Myntti (St. Augustine, FL)
Assignee: OSARTIS GmbH
A61K31/194A61K33/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,691,085
App. No.
18/270,005
Filed
Jun 28, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1627
USPC
514/574
Abstract

A method for selectively or preferentially reducing the amount of Fe ions available to cancer cells involves introducing to an area of the body which contains cancer cells an effective amount of an aqueous, pH buffered composition that includes dissociation products of a soluble weak acid and a salt of a weak acid. When the amount of arriving Fe ions falls below a first threshold, the cancer cell no longer can proliferate. When the amount of arriving Fe ions falls below a second threshold, the cancer cell dies.

Claims (24)

1 . A treatment method involving selectively or preferentially reducing the amount of Fe ions available to cancer cells or pre-cancerous cells, said method comprising introducing to an area of a body which contains such cells an effective amount of a buffered composition that consists of (a) a solvent component that comprises water and (b) a solute component that comprises anions of a soluble weak acid, hydronium ions, and cations of a strong base, said composition having a pH of 6.5 or less.

2 . The method of claim 1 wherein said soluble weak acid is citric acid.

3 . The method of claim 2 wherein said cations of a strong base are alkali metal ions.

4 . The method of claim 1 wherein said composition has an effective solute concentration of at least 0.5 Osm/L.

5 . The method of claim 4 wherein said composition has an effective solute concentration of at least 0.75 Osm/L.

6 . The method of claim 4 wherein said composition has a pH from 3.0 to 6.5.

7 . The method of claim 6 wherein said composition has a pH from 3.2 to 6.0.

8 . The method of claim 7 wherein said composition has a pH from 3.4 to 5.5.

9 . The method of claim 1 wherein said composition has a pH from 3.0 to 6.5.

10 . The method of claim 9 wherein said composition has a pH from 3.2 to 6.0.

11 . The method of claim 10 wherein said composition has a pH from 3.4 to 5.5.

12 . The method of claim 1 wherein said solvent component consists of water.

13 . The method of claim 12 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

14 . The method of claim 1 wherein said solvent component consists of water and no more than 25% (w/v) of one or more organic liquids.

15 . The method of claim 14 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

16 . The method of claim 14 wherein said solute component further comprises an active anti-cancer agent.

17 . The method of claim 16 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

18 . The method of claim 1 wherein each of the following is true:

said soluble weak acid is citric acid,

said cations of a strong base are alkali metal ions,

said composition has an effective solute concentration of at least 0.75 Osm/L, and

said composition has a pH from 3.4 to 5.5.

19 . The method of claim 18 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

20 . The method of claim 18 wherein said solute component is free of surfactants.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2025
From: NEXT SCIENCE IP HOLDINGS PTY LTD
To: OSARTIS GMBH
Reel/Frame 072590/0763 →
Continuity (2)
Provisional Application 63131726 · Dec 29, 2020
Related Publication 20240091181A1 · Mar 21, 2024
References Cited (41)
US 9427417B2 · Myntti · 2016 [cited by applicant]
US 10477860B2 · Myntti · 2019 [cited by examiner]
US 20160038604A1 · Holbein · 2016 [cited by examiner]
US 20200163938A1 · Nishida et al. · 2020 [cited by applicant]
WO 2022147055A1 · 2022 [cited by applicant]
Frawley et al. The Ins and Outs of Bacterial Iron Metabolism, Mol Microbiol, Aug. 2014, pp. 1-13. (Year: 2014). [cited by examiner]
Bates, George, W., et al., “The Kinetics and Mechanism of Iron (III) Exchange between Chelates and Transferrin”, The Journal of Biological Chemistry, vol. 242, No. 12, Issue of Jun. 25, 1967, pp. 2810-2815. [cited by applicant]
Brinckerhoff, C.E., et al., “Matrix metalloproteinases: a tail of a frog that became a prince”, Nature Reviews, Molecular Cell Biology, vol. 3, Mar. 2002, pp. 207-214. [cited by applicant]
Byrne, Shaina L., et al., “The Unique Kinetics of Iron Release from Transferrin: The Role of Receptor, Lobe-Lobe Interactions and Salt at Endosomal pH”, J. Mol. Biol. Feb. 12, 2010; 396(1): 130. doi: 10.1016/j.jmb, Nov.… [cited by applicant]
Cathcart, J., et al., “Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas”, ScienceDirect, Genes & Diseases, 2015, vol. 2, pp. 26-34. [cited by applicant]
Clinical Study Report, “Clinical Assessment of the Effects of Next Science Wound Gel on Diagnostic Biopsy Wound Sites of Suspected Non-Melanoma Skin Cancer Lesions”, Protocol No. CSP-011, Next Science, Sep. 20, 2021, pp… [cited by applicant]
De Saint Jean, Magdalena, et al., “Effects of Benzalkonium Chloride on Growth and Survival of Chang Conjunctival Cells”, Investigative Ophthalmology & Visual Science, Mar. 1999, vol. 40, No. 3, pp. 619-630. [cited by applicant]
Decaneto, Elena, et al., “Solvent water interactions within the active site of the membrane type I matrix metalloproteinase”, Phys. Chem. Chem. Phys., 2017, vol. 19, pp. 30316-30331. [cited by applicant]
El Hage Chahine, Jean-Michel, et al., “The mechanism of iron release from transferrin: Slow-proton-transfer-induced loss of nitrilotriacetatoiron(III) complex in acidic media”, Eur. J. Biochem., 223, pp. 581-587 (1994). [cited by applicant]
Enomoto, R., et al., “Cationic Surfactants Induce Apoptosis in Normal and Cancer Cells”, ANNALS New York Academy of Sciences, 2007, pp. 1-6. [cited by applicant]
Gaur, K., et al., “Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy”, Inorganics, Nov. 6, 2018, 126, pp. 1-38. [cited by applicant]
Gialeli, Chrisostomi, et al., “Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting”, the FEBS Journal 278 (2011), pp. 16-27. [cited by applicant]
Gomis-Ruth, F. Xavier, “Catalytic Domain Architecture of Metzincin Metalloproteases”, The Journal of Biological Chemistry, Jun. 5, 2009, vol. 284, No. 23, pp. 15353-15357. [cited by applicant]
Lee, David A., et al., “The pH-Induced Release of Iron from Transferrin Investigated with a Continuum Electrostatic Model”, Biophysical Journal, vol. 74, Jun. 1998, pp. 2747-2759. [cited by applicant]
Lui, Goldie Y.L., et al., “Targeting cancer by binding iron: Dissecting cellular signaling pathways”, Oncotarget, vol. 6, No. 22, Jun. 23, 2015, 18748-18779. [cited by applicant]
Muri, E.M.F., et al., “Hydroxamic Acids as Pharmacological Agents”, Current Medicinal Chemistry, 2002, 9, pp. 1631-1653 (with cover page). [cited by applicant]
Next Science—2019 Annual Report, Sydney, Australia, Thursday, Apr. 9, 2020, Next Science, 77 total pages. [cited by applicant]
Next Science Clinical Study Protocol 011, “Clinical Assessment of the Effects of Next Science Wound Gel on Diagnostic Biopsy Wound Sites of Suspected Non-Melanoma Skin Cancer Lesions”, Next Science Ltd., Jan. 22, 2020, … [cited by applicant]
Next Science Limited 2019 Annual General Meeting, Wednesday, Sep. 25, 2019, Next Science, 7 pages. [cited by applicant]
Next Science Limited 2020 Annual General Meeting, Wednesday, May 6, 2020, Next Science, 6 pages. [cited by applicant]
Next Science Limited AGM Presentation, Innovations powered by XBIO technology, Next Science, May 6, 2020, 16 pages. [cited by applicant]
Next Science Limited Annual General Meeting—presentation, Innovations powered by XBIO technology, Next Science 2019 AGM Presentation, Sep. 25, 2019, 26 pages. [cited by applicant]
Next Science/JCCR Master Collaboration Agreement, Master Agreement for Specimen Acquisition Collaboration, May 28, 2014, 12 pages. [cited by applicant]
Ren, Jian-Guo, et al., “Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway”, Scientific Reports, Jul. 3, 2017, pp. 1-13. [cited by applicant]
Reunanen, N., et al., “Matrix Metalloproteinases in Cancer Cell Invasion”, Madame Curie Bioscience Database—NCBI Bookshelf, 2018, pp. 1-21. [cited by applicant]
Rundhaug, Joyce E., “Matrix Metalloproteinases, Angiogenesis, and Cancer”, Clinical Cancer Research, vol. 9, Feb. 2003, pp. 551-554. [cited by applicant]
Sans-Fons, M. Gloria, et al., “Matrix Metalloproteinase-9 and Cell Division in Neuroblastoma Cells and Bone Marrow Macrophages”, Growth Factors, Cytokines, Cell Cycle Molecules, The American Journal of Pathology, vol. 1… [cited by applicant]
Spiro, Thomas G., et al., “The Hydrolytic Polymerization of Ferric Citrate. I. The Chemistry of the Polymer”, Journal of the American Chemical Society, 89, 22, Oct. 25, 1967, pp. 5555-5559. [cited by applicant]
Spiro, Thomas G., et al., “The Hydrolytic Polymerization of Ferric Citrate. II. The Influence of Excess Citrate”, Journal of the American Chemical Society, 89:22, Oct. 25, 1967, pp. 5559-5562. [cited by applicant]
Tallant, C., et. al., “Matrix metalloproteinases: Fold and function of their catalytic domains”, Biochimica et Biophysica Acta, 1803, 2010, pp. 20-28. [cited by applicant]
Wang, J., et al., “Regulation of cellular iron metabolism”, Biochem. J., 2011, vol. 434, pp. 365-381. [cited by applicant]
Yip, Kenneth W., et al., “Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen”, Cancer Therapy: Preclinical, Clin Cancer Res 2006; 12(18), Sep. 15, 2006, pp. 5557-5569 … [cited by applicant]
Yu, Qin, et al., “Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis”, Genes & Development, 14, 2000, pp. 163-176 (with cover page). [cited by applicant]
EPO extended search report in EP appl. No. 21916377.1, mailed Nov. 6, 2024. [cited by applicant]
A. Levina et al., “Transferrin Cycle and Clinical Roles of Citrate and Ascorbate in Improved Metabolism,” ACS Chem. Biol., vol. 14, pp. 893-900, Apr. 11, 2019 (American Chemical Society; Washington, DC). [cited by applicant]
J.L. Heath et al., “Iron Deprivation in Cancer—Potential Therapeutic Implications,” Nutrients, vol. 5, pp. 2836-2859, Jul. 24, 2013 (MDPI; Basel, Switzerland). [cited by applicant]